Biomarin

10 key clinical trials to watch in the first half of 2021
BioPharma Dive
Sun, 01/17/21 - 05:01 pm
clinical trials
Novavax
AstraZeneca
JNJ
vaccines
COVID-19
Biomarin
Amgen
Merck
Pfizer
Roche
SAGE Therapeutics
Biogen
Vertex Pharmaceuticals
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Mon, 01/11/21 - 10:40 am
Biomarin
hemophilia A
gene therapy
clinical trials
Roctavian
10 Biopharma Stories to Look Forward to in 2021
BioSpace
Sun, 01/3/21 - 04:39 pm
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
Mon, 12/7/20 - 10:32 am
ASH2020
uniQure
hemophilia A
Sangamao
gene therapy
Biomarin
Deep Genomics hits the partnering ground running with BioMarin deal
Fierce Biotech
Tue, 11/17/20 - 10:50 am
Deep Genomics
Biomarin
drug discovery
artificial intelligence
How BioMarin Beat Expectations in Q3
Motley Fool
Fri, 11/6/20 - 09:55 am
Biomarin
hemophilia A
earnings
BioMarin nabs FDA review for dwarfism drug vosoritide, forgoes AdComm as it eyes 2021 approval
Fierce Biotech
Wed, 11/4/20 - 10:57 pm
Biomarin
FDA
vosoritide
dwarfism
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
Yahoo/Zacks.com
Fri, 08/21/20 - 11:56 am
Biomarin
FDA
achondroplasia
dwarfism
2 major FDA rejections leave some pharma investors worried about intensification of regulations
Beckers Hospital Review
Thu, 08/20/20 - 10:51 pm
FDA
drug approvals
drug development
Gilead Sciences
Biomarin
Is valrox dead?
EP Vantage
Thu, 08/20/20 - 11:09 am
Biomarin
hemophilia A
valrox
gene therapy
Roche
Pfizer
FDA
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
Fierce Biotech
Wed, 08/19/20 - 09:28 am
Biomarin
FDA
valrox
hemophilia A
How Biomarin Beat Expectations in Q2
Motley Fool
Wed, 08/5/20 - 09:46 am
Biomarin
earnings
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
Wed, 07/29/20 - 10:54 am
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Sat, 07/25/20 - 02:25 pm
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
Wed, 06/24/20 - 11:21 pm
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Wed, 06/17/20 - 10:00 pm
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Mon, 06/1/20 - 10:42 am
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Yahoo/PR Newswire
Sun, 05/3/20 - 07:53 pm
Biomarin
DiNAQOR
gene therapy
cardiomyopathy
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
Motley Fool
Thu, 04/30/20 - 10:25 am
Biomarin
earnings
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox

Pages